

The molecular mechanism of contrast-induced nephropathy (CIN) and its link to in vitro studies on iodinated contrast media (CM)

Follow this and additional works at: <https://www.biomedicinej.com/biomedicine>

Recommended Citation

Yang, Jai-Sing; Peng, Yan-Ru; Tsai, Shih-Chang; Tyan, Yeu-Sheng; Lu, Chi-Cheng; Chiu, Hong-Yi; Chiu, Yu-Jen; Kuo, Sheng-Chu; Tsai, Yuh-Feng; Lin, Ping-Chin; and Tsai, Fuu-Jen () "The molecular mechanism of contrast-induced nephropathy (CIN) and its link to in vitro studies on iodinated contrast media (CM)," *BioMedicine*: Vol. 8 : Iss. 1 , Article 5.

DOI: [10.37796/2211-8039.1603](https://doi.org/10.37796/2211-8039.1603)

This Original Article is brought to you for free and open access by BioMedicine. It has been accepted for inclusion in BioMedicine by an authorized editor of BioMedicine.

Review article

The molecular mechanism of contrast-induced nephropathy (CIN) and its link to *in vitro* studies on iodinated contrast media (CM)

Jai-Sing Yang^{1,†}, Yan-Ru Peng^{2,†}, Shih-Chang Tsai³, Yeu-Sheng Tyan^{4,5,6}, Chi-Cheng Lu⁷, Hong-Yi Chiu⁷,
Yu-Jen Chiu⁸, Sheng-Chu Kuo^{9,10}, Yuh-Feng Tsai^{11,12}, Ping-Chin Lin¹³, Fuu-Jen Tsai^{14,15,16,*}

¹Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 404, Taiwan

²School of Medicine, China Medical University, Taichung 404, Taiwan

³Department of Biological Science and Technology, China Medical University, Taichung 404, Taiwan

⁴Department of Medical Imaging, Chung Shan Medical University Hospital, Taichung 402, Taiwan

⁵School of Medical Imaging and Radiological Sciences, Chung Shan Medical University, Taichung 402, Taiwan

⁶School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan

⁷Department of Pharmacy, Buddhist Tzu Chi General Hospital, Hualien 970, Taiwan.

⁸Division of Reconstructive and Plastic Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 112, Taiwan.

⁹Chinese Medicinal Research and Development Center, China Medical University Hospital, China Medical University, Taichung 404, Taiwan

¹⁰School of Pharmacy, China Medical University, Taichung 404, Taiwan

¹¹Department of Diagnostic Radiology, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei 111, Taiwan

¹²School of Medicine, Fu-Jen Catholic University, Taipei 242, Taiwan

¹³Department of Medical Imaging, Chia-Yi Christian Hospital, Chiayi 600, Taiwan

¹⁴Genetics Center, Department of Medical Research, China Medical University Hospital, Taichung 404, Taiwan

¹⁵School of Chinese Medicine, China Medical University, Taichung 404, Taiwan

¹⁶Department of Medical Genetics, China Medical University Hospital, Taichung 404, Taiwan

Received 30th of October, 2017 Accepted 7th of November, 2017

© Author(s) 2018. This article is published with open access by China Medical University

Keywords:

Iodinated contrast media;
The management of
anaphylactic reaction by
iodinated contrast media;
Dose for non-ionic
contrast media;
Contrast-induced
nephropathy (CIN);
In vitro studies on
iodinated contrast media.

ABSTRACT

Iodinated contrast media (iodinated CM) have increased ability to absorb x-rays and to visualize structures that normally are impossible to observe in a radiological examination. The use of iodinated CM may destroy renal function, commonly known as contrast-induced nephropathy (CIN), which can result in acute renal failure (ARF). This review article mainly focuses on the following areas: (1) classifications of iodinated CM: ionic or non-ionic, high-osmolarity contrast media (HO CM), low-osmolarity contrast media (LO CM) and iso-osmolarity contrast media (IO CM); (2) an introduction to the physical and chemical properties of the non-ionic iodinated CM; (3) the management of anaphylactic reaction by iodinated CM; (4) a suggested single injection of adult doses and maximum dose for non-ionic iodinated CM; (5) the molecular mechanism of contrast-induced nephropathy (CIN); (6) *In vitro* studies on iodinated CM. Based on above information, this review article provide an insight for understanding the drug safety of iodinated CM.

1. Introduction

Iodinated contrast media (iodinated CM) absorb x-rays and visualize structures that are normally hard to observe in a radiological examination [1-4]. It has been used widely for many years. Contrast media provide an ability to enhance normal structures or pathological lesions, which makes these places look different

from surrounding. The mechanism of iodinated contrast media is based on shielding effect: high energy x-ray penetrates substances and yields a dark place in a plane image. Iodine, the content of iodinated contrast media, absorbs the energy of x-ray; that is to say, iodinated CM “shield” x-ray from detector and lead to a high density, white “shadow” appearing. Iodinated CM elevate the sensitivity and diagnostic accuracy in radiological examination

[†] These authors contributed equally to this work.

* Corresponding author. Department of Medical Research, China Medical University Hospital, China Medical University, No. 2, Yuh-Der Road, Taichung 404, Taiwan
E-mail address: d0704@mail.cmuh.org.tw (F.-J. Tsai).





Ionization	Ionic	Non-ionic
Monomers		
Example	Diatrizoate(Hypaque®) Iothalamate(Conray®)	Iopamidol(Iopamiro®) Iopromide(Ultravist®) Iohexol(Omnipaque®) Ioversol(Optiray®) Iobitridol(Xenetix®)
Dimers		
Example	Ioxaglate (Hexabrix®)	Iodixanol(Visipaque®)

Fig. 1 - Water-soluble iodinated CM are divided into four groups based on the structure. They are ionic monomer, ionic dimer, nonionic monomer and nonionic dimer.

Table 1 – The biologic adverse reaction between ionic and non-ionic contrast media.

Biologic adverse reaction	Ionic contrast media	Non-ionic contrast media
Thermal effect	Moderate	Mild to less
Pain during injection	Moderate	Mild to less
Nausea and vomiting	Moderate	Mild to less
Toxicity to kidney	Higher	Lower
Tissue necrosis when extravasation occurs	More severe	Less severe
Other allergic effects	Often (around 10%)	Seldom (lower than 5%)

[1, 5-7].

Based on the solubility, iodinated CM are divided into three groups: oily iodinated CM, water-soluble iodinated CM and water-insoluble iodinated CM [8-10]. Iodinated CM are usually classified into ionic iodinated CM and non-ionic iodinated CM [10, 11]. Generally, ionic contrast media have higher osmolality, higher toxicity and higher anaphylactic reaction. Non-ionic contrast media possess lower osmolality, lower toxicity and lower anaphylactic reaction [12, 13]. Based on the structure, iodinated CM are divided into four groups: ionic monomer, ionic dimer, nonionic monomer and nonionic dimer (Fig. 1). Based on the osmolality, iodinated CM are classified into high-osmolar contrast media (HOCM), low-osmolar contrast media (LOCM) and iso-osmolar contrast media (IOCM). High-osmolar contrast media (HOCM) is characterized by osmolality of above 1500 mOsm/kg H₂O. Low osmolar contrast media (LOCM) is characterized by osmolalities within a relatively wide range of 300-900 mOsm/kg H₂O. The iso-osmolar contrast media (IOCM) is characterized by osmolality level similar to that of blood (290 mOsm/kg H₂O) [14, 15]. The osmolality of high-osmolar contrast media (HOCM) is up to 7 or 8 fold greater than blood and has been associated

with high risk of adverse drug reactions (ADR) and renal toxicity. Since the late 1960s, the nonionic low-osmolar contrast media (LOCM) have been developed to better safety and replace ionic iodinated CM for clinical uses. In 1996, the US Food and Drug Administration (FDA) approved the iso-osmolar contrast media (IOCM), iodixanol (Visipaque®), to have a better safety profile [14]. Furthermore, discomfort such as pain and heat associated with the injection site was found to be lower when using iso-osmolality contrast media (IOCM) than low osmolar contrast media (LOCM) [14]. It is low neuro-toxicity and low osmolality that are important to intrathecal route injected contrast media, such as Iopamidol (Iopamiro®) 300 and Iohexol (Omnipaque®) 300 [16, 17]. Table 1 shows the biologic adverse drug reaction (ADR) difference between ionic iodinated CM and non-ionic iodinated CM. Currently used non-ionic iodinated CM in Taiwan and their chemical properties are summarized in Table 2. The chemical structures of non-ionic iodinated CM are shown in Fig. 2 [3, 11, 18-31]. In Table 3, we summarized the suggested single injection of adult doses and maximum dose for non-ionic iodinated CM by intra-arterial route. In Table 4, we summarized the suggested single injection of adult doses and maximum dose for non-ionic

Table 2 – The chemistry and physical properties of non-ionic contrast media in Taiwan [31].

Brand name	Iopamiro	Ultravist	Omnipaque	Optiray	Xenetix	Visipaque
Generic name	Iopamidol	Iopromide	Iohexol	Ioversol	Iobitridol	Iodixanol
Iodine concentration (mgI/ml)			140			
	200	150	180	240	250	270
	250	240	210	300	300 (Taiwan)	320 (Taiwan)
	300 (Taiwan)	300 (Taiwan)	240	320 (Taiwan)	350 (Taiwan)	
	370 (Taiwan)	370 (Taiwan)	300 (Taiwan)	350 (Taiwan)		
			350 (Taiwan)			
Osmolality (mOsmo/kg H ₂ O, 37°C)			322			
	413	328	408	502	585	290 (Taiwan)
	524	483	460	651	695 (Taiwan)	
	616 (Taiwan)	607 (Taiwan)	520	702 (Taiwan)	915 (Taiwan)	
	796 (Taiwan)	774 (Taiwan)	672 (Taiwan)	792 (Taiwan)		
			844 (Taiwan)			
	Low osmolality	Low osmolality	Low osmolality	Low osmolality	Low osmolality	Iso-osmolality
Viscosity (mPa-s, 37°C)			1.5			
	2.0	1.5	2.0	3.0	4.0	11.8 (Taiwan)
	3.0	2.8	2.5	5.5	6.0 (Taiwan)	
	4.7 (Taiwan)	4.9 (Taiwan)	3.4	5.8 (Taiwan)	10.0 (Taiwan)	
	9.4 (Taiwan)	10.0 (Taiwan)	6.3 (Taiwan)	9.0 (Taiwan)		
			10.4 (Taiwan)			
Median lethal dose (LD ₅₀)	21.8 g I/Kg	18.5 g I/Kg	18.5 g I/Kg	17.0 g I/Kg	15.9 g I/Kg	17.9 g I/Kg
Expiration duration	5 years	3 years	3 years	3 years	3 years	3 years
National Health Insurance in Taiwan (NHI), 2017	Cover	Cover	Cover	Cover	Cover	Self-paid
Administration	Intravenous injection; intra-arterial injection; Intrathecal injection (Iopamiro 300, Omnipaque 300); Oral					Intravenous injection
Uses	Computed tomography (CT); Angiocardigraphy; Arteriography of cerebral arteries; Pyelography; Peripheral angiography					Angiocardigraphy Computed tomography (CT)

iodinated CM by intravenous route. In Table 5, we summarized the suggested single injection of adult doses and maximum dose for non-ionic iodinated CM by intrathecal route.

2. The adverse drug reaction (ADR) of iodinated contrast media and management

ADR caused by iodinated CM includes chemical and constitutional effects. Chemical effects are mainly referred as contrast-induced nephropathy (CIN) and will be discussed later. Anaphylactic reaction is the most common situation in constitutional effect and may cause mild symptom such as nausea and vomiting, dizziness, rash and itch, or chest discomfort, shock in more severe situation, or even death [21, 23, 28, 29, 32]. Iodinated contrast media cause little allergic reactions, especially for low-osmolar contrast media (LOCM). The incidence of adverse effect to LOCM is 2 to 7/1000, that of severe allergic reaction to LOCM is lower 1 to 4/100,000, and that of lethal rate to LOCM is around 2-9/1000,000 [33, 34]. We should recognize adverse effects and receive early intervene to reverse bad situation. The management and treatment of adverse effects on anaphylactic reaction by Advanced Cardiovascular Life Support (ACLS) guideline is shown in Fig. 3. The Fig. 4 shows that management and treatment of anaphylactic reaction by iodinated CM is proposed in 2017 RSROC Contrast

Media Manual [33]. There are several affecting factors for anaphylactic reaction by iodinated CM such as particularly allergy (arising from consuming sea foods or drugs), previous adverse reactions, history of asthma or bronchospasm, history of allergy, cardiac disease, dehydration, haematological and metabolic conditions (sickle cell anaemia, patients with thrombotic tendency), renal disease, neonates, old patients, anxiety and apprehension medications (β -blockers, interleukin-2 (IL-2), aspirin, NSAIDs) [33]. In addition, IOCM (ie, iodixanol (Visipaque®)) are associated with the highest risk of causing a delayed hypersensitivity reactions. The incidence of delayed hypersensitivity reactions to IOCM is 10.9% and 5%-6% for LOCM [33, 35, 36]. Lasser *et al.* suggested that two doses of corticosteroid prophylaxis (32 mg of methyl prednisolone, orally 12 and 24 h before iodinated CM injection) significantly reduced the iodinated CM-induced anaphylactic reaction [13, 34].

3. Molecular mechanism of contrast-induced nephropathy (CIN)

CIN is one of chemical adverse effects of iodinated CM. The pathophysiology of CIN is related to hemodynamic changes caused by vasoconstriction which makes a decrease of glomerular filtration rate (GFR) and a renal ischemia. Direct cytotoxic-




Fig. 2 - The chemical structures of currently used non-ionic iodinated CM.

ity to renal tubular cell is another pathway leading to kidney damage [37-49]. Norbert H. *et al.* medullary ischemia and direct cytotoxicity to renal tubular cell are two main mechanism to result in CIN. Medullary ischemia is a complex result of vasoconstriction, lower oxygen delivery and higher oxygen demand. In Fig. 5, there are three factors such as increasing oxidative stress, enhancing renal vasoconstriction and inducing tubular cell damage responsible for CIN [50, 51]. Several factors including renal ischemia, particularly in the medulla, reactive oxygen species (ROS) formation, reduction of nitric oxide production, tubular epithelial and vascular endothelial injury may be implicated in CIN. Many studies demonstrated that iodinated CM exert cytotoxic effects and renal tubular epithelial cells present severe cell death by autophagy and/or apoptosis [6]. Iodinated CM induces renal vasoconstriction by increase of adenosine and endothelin, and changes the blood flow from the medulla to the cortex and GFR are reduced. Reduction in renal blood flow can increase ROS release by oxidative stress. In tubular cells, iodinated CM directly caused osmotic necrosis or vacuolization leading to acute tubular cell death [15, 37-39]. Several antioxidant compounds have been demonstrated prevention effects by CIN, including sodium bicarbonate, N-acetylcysteine (NAC), ascorbic acid, statins, and recently, phosphodiesterase type 5 inhibitors [4-7]. The detailed molecular mechanisms of CIN are described in Fig. 6.

4. *In-vitro* studies on contrast-induced nephropathy (CIN) by iodinated CM.

In 2017 year, Charalampos Mamoulakis *et al.* summarize recent *in vivo* studies on oxidative stress related to CIN in animal mod-

els and humans [6]. Hereby, we summarize recent *in vitro* studies on the mechanisms in contrast-induced nephropathy (CIN). Direct damage, a risk factor of CIN, induces cell death to renal tubular cells caused by iodinated CM. Table 6 is a summary of the manifestation of CIN which is collected from *in vitro* studies. Inhibiting cell proliferation and inducing cell death are found in renal cell lines including KRK52-E, LLC-PK1, HKCS, HK-2 at the concentration higher than 75 mgI/ml. Importantly, iodinated CM induced cell death no matter whether in LOCM or IOCM. Apoptosis and/or autophagy are two cell types in cell death [52-58]. Readers refer to our previous article for detailed molecular mechanisms of apoptosis and autophagy [59].

5. Conclusion

Autophagy and apoptosis were associated with the pathophysiology of CIN in *in vitro* reports. In conclusion, *in vitro* studies showed that increased cell death by apoptosis and/or autophagy was demonstrated in the kidney cell lines after the administration of iodinated CM. Inhibition of autophagy induced cell apoptosis suggested the protective role of autophagy in CIN. In the future, studies about how to reduce cellular stress and cell death by new methods or new compounds and understanding the details molecular mechanisms may be helpful for the development of new therapeutic strategies for the treatment of CIN.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Table 3 – Suggested single injection of adult doses and maximum total dose for non-ionic contrast media by intra-arterial injection [31].

Non-ionic contrast media	Angiography of arteries of extremity	Femoral arteriography	Aortography	Arteriography	Arteriography of cerebral arteries	Cardiac ventriculography, Left (FDA Dosage)	Cardiac ventriculography, Left (Off label Dosage)	Coronary angiography (FDA Dosage)	Coronary angiography (Off label Dosage)	Inferior vena cavogram
Iopromide (Ultravist) (300 mgI/ml)	Adult doses suggestion	5-40 ml for subclavian or femoral artery 25-50 ml for aortic bifurcation			3-12 ml for carotid arteries 4-12 ml for vertebral arteries 20 to 50 ml for aortic arch injection					
	Maximum dose	250 ml			150 ml					
Iopromide (Ultravist) (370 mgI/ml)	Adult doses suggestion		Blood flow and vascular and pathological nature of the vessels of interest			30-60 ml	44-60 ml	3-14 ml for right or left coronary artery	7 to 10 ml (4-5 injections)-left coronary artery 7-10 ml (2 to 3 injections)-right coronary artery	Blood flow and vascular and pathological nature of the vessels of interest
	Maximum dose		225 ml			225 ml		225 ml		225 ml
Ioversol (Optiray) (320 mgI/ml)	Adult doses suggestion				2-12 ml	40 ml (30-50 ml)		45 ml (10-80 ml)		
	Maximum dose				200 ml					
Iobitridol (Xenetix) (350 mgI/ml)	Adult doses suggestion		10-80 ml			30-60 ml				
	Maximum dose		250 ml							
Iodixanol (Visipaque) (320 mgI/ml)	Adult doses suggestion			Carotid arteries: 10-14 ml Vertebral arteries: 10-12 ml Right coronary artery: 3-8 ml Left coronary artery: 3-10 ml Left ventricle: 20-45 ml Renal arteries: 8-18 ml Aortography: 30-70 ml Major aorta branch: 10-70 ml Peripheral arteries: 15-30 ml Aortofermoral runoffs: 20-90 ml	10-14 ml					
	Maximum dose			250 ml (80 gI)	175 ml (80 gI)					

Table 4 – Suggested single injection of adult doses and maximum total dose for non-ionic contrast media by Intravenous injection [31].

Non-ionic contrast media	Computerized axial tomography, Body	Computerized axial tomography of head (brain)	Computerized axial tomography of abdomen	Intravenous pyelogram (urography)	Angiocardiography-Coronary Arteriography/Ventriculography	Angiocardiography-ventriculography or nonselective opacification of multiple coronary arteries	Aortography	Arteriography, peripheral	Arteriography, selective visceral	Arteriography of cerebral arteries	Renal arteriography	Venography
Iopromide (Ultravist) (300 mgI/ml)	Adult doses suggestion	50-200 ml for bolus IV injection	50-200 ml		300 mgI/kg							
	Maximum dose	100-200 ml for rapid IV infusion	200 ml (60 gI)		100 ml (30 gI)							
Iopromide (Ultravist) (370 mgI/ml)	Adult doses suggestion	41-162 ml for bolus IV injection	41-162 ml									
	Maximum dose	81-162 ml for rapid IV infusion	162 ml (60 gI)									
Iopamiro (Iopamidol) (300 mgI/ml)	Adult doses suggestion	100-200 ml	100-200 ml	2.0-2.5 ml/Kg	50 ml			5-40 ml for femoral or subclavian		8-12 ml		
	Maximum dose	200 ml (60 gI)	200 ml (60 gI)					25-50 ml for aorta for a distal runoff		90 ml		
Iopamiro (Iopamidol) (370 mgI/ml)	Adult doses suggestion	81-162 ml			40 ml	2-10 ml	25-50 ml	50 ml		50 ml-larger vessels		
	Maximum dose	81-162 ml								10 ml-renal arteries		
Omnipaque (Iohexol) (300 mgI/ml)	Adult doses suggestion	50-200 ml	75-150 ml		200-350 mgI/Kg			30-90 ml		6-12 ml-Common carotid artery; 8-10 ml-Internal carotid artery; 6-9 ml-External carotid artery; 6-10 ml-Vertebral artery.		
	Maximum dose									291 ml		
Omnipaque (Iohexol) (350 mgI/ml)	Adult doses suggestion	60-100 ml	350 ml		200-350 mgI/Kg	5 ml (3-14 ml)	40 ml (30-60 ml)	20-70 ml		50-80 ml-aorta, 30- 60 ml-branches, 5 -15 ml-renal arteries.		
	Maximum dose									250 ml		
Ioversol (Optiray) (320 mgI/ml)	Adult doses suggestion	25-75 ml (bolus injection)	50-150 ml		50-75 ml	8 ml (2-10 ml) for the left coronary; 6 ml (1-10 ml) for the right coronary artery.					9 ml (6-15 ml)	
	Maximum dose	150 ml				250 ml					250 ml	
Ioversol (Optiray) (350 mgI/ml)	Adult doses suggestion	25-75 ml (bolus injection)			50-75 ml							50-100 ml
	Maximum dose	150 ml										250 ml
Iobitridol (Xenetix) (300 mgI/ml)	Adult doses suggestion				50-100 ml				30-60 ml (3-5 ml/Kg)			
	Maximum dose											
Iobitridol (Xenetix) (350 mgI/ml)	Adult doses suggestion	Depend on the organs under investigation, the diagnostic problem and, in particular, the different scan and image-reconstruction times of the scanners in use	1-1.5 ml/Kg	155-330 ml					30-60 ml (3-5 ml/Kg)	10-80 ml	105-205 ml	
	Maximum dose	1-1.5 ml/Kg								250 ml		
Iodixanol (Visipaque) (320 mgI/ml)	Adult doses suggestion	75-150 ml	75-150 ml		1 ml/Kg	20 ml						
	Maximum dose	150 ml (80 gI)	150 ml (80 gI)		100 ml (80 gI)							

Table 5 – Suggested single injection of adult doses and maximum total dose for non-ionic contrast media by Intrathecal route injection [31].

Non-ionic contrast media		Myelogram - cervical myelogram (via lumbar injection)	Myelogram - total columnar myelography	Myelogram -thoracic	Myelogram -spinal cord
Iopamiro (Iopamidol) (300 mgI/ml)	Adult doses suggestion	10 ml	10 ml		
	Maximum total dose				
Iohexol (Omnipaque) (300 mgI/ml)	Adult doses suggestion	4-10 ml		6-10 ml	6-10 ml
	Maximum total dose	3060 mgI		3060 mgI	3060 mgI




Fig. 3 - Advanced Cardiovascular Life Support (ACLS) guideline for the management and treatment of adverse effects on anaphylactic reaction.

Acknowledgments

This work was supported by the grant from China Medical University Hospital, Taichung, Taiwan (DMR-107-123). The authors also would like to express our gratitude to Miss Huei-Min Chen for drug information supports.

Open Access This article is distributed under terms of the Creative

Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided original author(s) and source are credited.

REFERENCES

- [1] La Grutta L, Toia P, Maffei E, Cademartiri F, Lagalla R, Midiri M. Infarct characterization using CT. *Cardiovasc Diagn Ther.* 2017; 7: 171-88.




Fig. 4 - Management and treatment of anaphylactic reaction by iodinated CM is proposed in 2017 RSROC Contrast Media Manual.




Fig. 5 - Three factors are responsible for contrast-induced nephropathy.

[2] Rybicki FJ, Piazzi K, Prior R, Wake N, Dill KE. Iodinated contrast injection data from a new technology. *Radiol Technol.* 2012; 84: 120-5.

[3] Meunier B, Joskin J, Damas F, Meunier P. Iodinated contrast media and iodine allergy: myth or reality? *Rev Med Liege.* 2013; 68: 465-9.

[4] Goodwill PW, Saritas EU, Croft LR, Kim TN, Krishnan KM, Schaffer DV, *et al.* X-space MPI: magnetic nanoparticles for safe medical imaging. *Adv Mater.* 2012; 24: 3870-7.

[5] Harbron RW, Ainsbury EA, Bouffler SD, Tanner RJ, Eakins JS, Pearce MS. Enhanced radiation dose and DNA damage associated with iodinated contrast media in diagnostic x-ray imaging. *Br J Radiol.* 2017;20170028.

[6] Mamoulakis C, Tsarouhas K, Fragkiadoulaki I, Heretis I, Wilks MF, Spandidos DA, *et al.* Contrast-induced nephropathy: Basic concepts, pathophysiological implications and prevention strategies. *Pharmacol Ther.* 2017.

[7] Prezzi D, Khan A, Goh V. Perfusion CT imaging of treatment response in oncology. *Eur J Radiol.* 2015; 84: 2380-5.

[8] Price DB, Ortiz AO. Myelography: From Lipid-Based to Gadolinium-Based Contrast Agents. *Magn Reson Imaging Clin N Am.* 2017; 25: 713-24.

[9] Cheng KT. Lipiodol-loaded poly(oxyethylene)-block-poly(oxypropylene)-block-poly(oxyethylene) triblock copolymers/polyethylene glycol-nanoparticles. In: *Molecular Imaging and Contrast Agent Database (MICAD)*. ed. Bethesda (MD): 2004.

[10] Cheng KT. Ioxilan carbonate particles. In: *Molecular Imaging and Contrast Agent Database (MICAD)*. ed. Bethesda (MD): 2004.

[11] Lee SY, Rhee CM, Leung AM, Braverman LE, Brent GA, Pearce EN. A review: Radiographic iodinated contrast media-induced thy-




Fig. 6 - The detailed molecular mechanisms of contrast-induced nephropathy.

- roid dysfunction. *J Clin Endocrinol Metab.* 2015; 100: 376-83.
- [12] Costa N. Understanding contrast media. *J Infus Nurs.* 2004; 27: 302-12.
- [13] Bettmann MA, Morris TW. Recent advances in contrast agents. *Radiol Clin North Am.* 1986; 24: 347-57.
- [14] Spampinato MV, Abid A, Matheus MG. Current Radiographic Iodinated Contrast Agents. *Magn Reson Imaging Clin N Am.* 2017; 25: 697-704.
- [15] Schrader R. Contrast material-induced renal failure: an overview. *J Interv Cardiol.* 2005; 18: 417-23.
- [16] Pugh ND, Griffith TM, Karlsson JO. Effects of iodinated contrast media on peripheral blood flow. *Acta Radiol Suppl.* 1995; 399: 155-63.
- [17] Stolberg HO, McClennan BL. Ionic versus nonionic contrast use. *Curr Probl Diagn Radiol.* 1991; 20: 47-88.
- [18] ten Dam MA, Wetzels JF. Toxicity of contrast media: an update. *Neth J Med.* 2008; 66: 416-22.
- [19] Campbell KL, Hud LM, Adams S, Andrel J, Ballas SK, Feldman AM, *et al.* Safety of iodinated intravenous contrast medium administration in sickle cell disease. *Am J Med.* 2012; 125: 100 e11-6.
- [20] Katzberg RW, Barrett BJ. Risk of iodinated contrast material--induced nephropathy with intravenous administration. *Radiology.* 2007; 243: 622-8.
- [21] Runge VM. A review of contrast media research in 1999-2000. *Invest Radiol.* 2001; 36: 123-30.
- [22] McCullough PA. Renal safety of iodixanol. *Expert Rev Cardiovasc Ther.* 2006; 4: 655-61.
- [23] Mruk B. Renal Safety of Iodinated Contrast Media Depending on Their Osmolarity - Current Outlooks. *Pol J Radiol.* 2016; 81: 157-65.
- [24] Dawson P. The non-ionic isotonic contrast agents. Perspectives and controversies. *Eur Radiol.* 1996; 6 Suppl 2: S20-4.
- [25] Konen E, Apter S, Morag B, Itzhak Y. Iodinated contrast media: adverse reactions, prevention and treatment. *Harefuah.* 1995; 128: 719-23.
- [26] Singh J, Daftary A. Iodinated contrast media and their adverse reactions. *J Nucl Med Technol.* 2008; 36: 69-74; quiz 76-7.
- [27] Weisbord SD, Palevsky PM. Iodinated contrast media and the role of renal replacement therapy. *Adv Chronic Kidney Dis.* 2011; 18: 199-206.
- [28] Weisbord SD. Iodinated contrast media and the kidney. *Rev Cardiovasc Med.* 2008; 9 Suppl 1: S14-23.
- [29] Pintassilgo Santos A, Mascarenhas Gaivao A, Tavares A, Ferreira S. Iodinated contrast agents. *Acta Med Port.* 2009; 22: 261-74.
- [30] Erley C. Iodinated contrast agent-induced nephropathy. *Radiologe.* 2007; 47: 761-7.
- [31] <https://www.micromedexsolutions.com/home/dispatch/ssl/true>. Published 2017. Updated Accessed.
- [32] Hu XH, Gong XY, Hu P. Transient small bowel angioedema due to intravenous iodinated contrast media. *World J Gastroenterol.* 2012; 18: 999-1002.
- [33] 2017 RSROC Contrast Media Manual (<https://www.rsroc.org.tw/DB/Info/file/123-1.pdf>). <https://www.rsroc.org.tw/DB/Info/file/123-1.pdf>. Published 2017. Updated Accessed.
- [34] Thomsen HS, Morcos SK. Radiographic contrast media. *BJU Int* 2000; 86 Suppl 1:1-10.
- [35] Almen T. The etiology of contrast medium reactions. *Invest Radiol.* 1994; 29 Suppl 1: S37-45.
- [36] Beckett K.R, MAK, Langer J.M. Safe Use of Contrast Media: What the Radiologist Needs to Know. *Radiographics.* 2015; 35: 1738-50.
- [37] Modi K, Dulebohn SC. Contrast Induced Nephropathy. In: *StatPearls*. ed. Treasure Island (FL): 2017.
- [38] Ursta AA, Kharkov EI, Petrova MM, Ursta OV, Kotikov AR, Kiselev AN. Contrast induced nephropathy in the older age group patients. *Adv Gerontol.* 2017; 30: 306-10.
- [39] Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vas-

Table 6 – *In vitro* studies of mechanisms on contrast-induced nephropathy (CIN) in iodinated contrast media.

<i>In-vitro</i> cell lines	Iodinated contrast media	Dose	Time of treatment	Results	References
KRK52-E (Rat kidney epithelial cell)	Iodixanol (Visipaque) Ioversol (Optiray) Iohexol (Omnipaque) Iopromide (Ultravist)	150 mg/ml	0.5 h, 1 h, 3 h, 6 h, 12 h, 24 h.	1. Decreasing cell proliferation by MTT assay. 2. Induce cells death by Trypan blue assay. 3. Increasing apoptosis by hematoxylin-stained.	[60]
NRK52-E (Rat tubular cells)	Iohexol (Omnipaque)	100 mg/ml	24 h	1. Decreasing cell proliferation by MTT assay. 2. Increasing apoptotic cells by TUNEL assay. 3. Increasing caspase-3, caspase-9 and cytochrome c protein levels by western. 4. Decreasing cell viability by iohexol was aggravated with 3-MA pretreatment.	[61]
LLC-PK1 (Pig renal tubular epithelial cells)	Iohexol (Omnipaque) Iodixanol (Visipaque)	100 mg/ml	24 h	1. Decreasing cell proliferation by MTT assay. 2. Increasing apoptotic cells by TUNEL assay. 3. Increasing caspase-8, caspase-9 and caspase-3 protein levels by western.	[62]
HK-2 (human embryonic proximal tubule)	Iopamiro (Iopamidol)	200 mg/ml	0 h 12 h 24 h	1. Decreasing cell proliferation by MTT assay. 2. Increasing apoptotic cells by TUNEL assay. 3. The mRNA level of Bax was increased and Bcl-2 was decreased by qPCR. 4. Increasing Bax, caspase-3 protein levels and decreasing Bcl-2, HSP70 protein levels by western.	[63]
LLC-PK1 (Pig renal tubular epithelial cells)	Iodixanol (Visipaque)	4.7-75 mg/ml	2h, 24h	1. Decreasing cell proliferation by MTT assay.	[58]
HK-2 (human embryonic proximal tubule)	Iopromide (Ultravist)	40 mg/ml 20 mg/ml 10 mg/ml	24-72 h	1. Caused the breaking of intercellular connections and cell migration by scratch assay. 2. Increasing SGK, SNAIL1, CTGE, COL1A1 mRNA levels by qPCR	[64]
LLC-PK1 (Pig renal tubular epithelial cells)	Ioversol (Optiray)	100 mg/ml	24 h	1. Increasing caspase-3 protein activity by caspase-3 activity assay	[56]
HK-2 (human embryonic proximal tubule)	Ioversol (Optiray)	100 µL/ml 200 µL/ml	24 h	1. Decreasing cell proliferation by MTT and LDH assay.	[55]
HK-2 (human embryonic proximal tubule)	Iodixanol (Visipaque)	25 mg/ml 50 mg/ml 100 mg/ml 200 mg/ml	2 h, 4 h, 8 h, 24h	1. Decreasing cell proliferation by CellTiter 96 assay.	[53]
LLC-PK1 (Pig renal tubular epithelial cells)	Iodixanol (Visipaque)	18.75-75 mg/ml	24 h	1. Decreasing cell proliferation by BrdU assay 2. Increasing apoptotic cells by cytoplasmic oligonucleosomes ELISA assay.	[52]

cular surgery. Br J Anaesth 2016; 117 Suppl 2: ii63-ii73.

[40] Davenport MS, Cohan RH, Ellis JH. Contrast media controversies in 2015: imaging patients with renal impairment or risk of contrast reaction. AJR Am J Roentgenol. 2015; 204: 1174-81.
 [41] Homma K. Contrast-induced Acute Kidney Injury. Keio J Med. 2016; 65: 67-73.
 [42] McCullough PA, Choi JP, Feghali GA, Schussler JM, Stoler RM, Vallabahn RC, et al. Contrast-Induced Acute Kidney Injury. J Am Coll Cardiol. 2016; 68: 1465-73.

[43] Genovesi E, Romanello M, De Caterina R. Contrast-induced acute kidney injury in cardiology. G Ital Cardiol (Rome) 2016; 17: 984-1000.
 [44] Ozkok S, Ozkok A. Contrast-induced acute kidney injury: A review of practical points. World J Nephrol. 2017; 6: 86-99.
 [45] Chalikias G, Drosos I, Tziakas DN. Contrast-Induced Acute Kidney Injury: An Update. Cardiovasc Drugs Ther. 2016; 30: 215-28.
 [46] Mohammed NM, Mahfouz A, Achkar K, Raffie IM, Hajar R. Contrast-induced Nephropathy. Heart Views. 2013; 14: 106-16.

- [47] Wichmann JL, Katzberg RW, Litwin SE, Zwerner PL, De Cecco CN, Vogl TJ, *et al.* Contrast-Induced Nephropathy. *Circulation.* 2015; 132: 1931-6.
- [48] Contrast-Induced Nephropathy (CIN): Current State of the Evidence on Contrast Media and Prevention of CIN. In. *Comparative Effectiveness Review Summary Guides for Clinicians.* ed. Rockville (MD): 2007.
- [49] Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Contrast-Induced Nephropathy: An "All or None" Phenomenon? *Angiology.* 2015; 66: 508-13.
- [50] Lameire NH. Contrast-induced nephropathy--prevention and risk reduction. *Nephrol Dial Transplant.* 2006; 21: i11-23.
- [51] Bagshaw SM, Culleton BF. Contrast-induced nephropathy: epidemiology and prevention. *Minerva Cardioangiol.* 2006; 54: 109-29.
- [52] Heinrich MC, Scheer M, Heckmann M, Kuefner MA, Uder M. Iodixanol induces apoptotic and antiproliferative effects but no necrotic cell death in renal proximal tubular cells *in vitro*. *Rofo* 2009; 181: 349-54.
- [53] Yao L, Kolluru GK, Kevil CG, Zhang WW. Intravascular radiocontrast iodixanol increases permeability of proximal tubule epithelium: a possible mechanism of contrast-induced nephropathy. *Vasc Endovascular Surg.* 2013; 47: 632-8.
- [54] Lerch M, Keller M, Britschgi M, Kanny G, Tache V, Schmid DA, *et al.* Cross-reactivity patterns of T cells specific for iodinated contrast media. *J Allergy Clin Immunol.* 2007; 119: 1529-36.
- [55] Zager RA, Johnson AC, Hanson SY. Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity. *Kidney Int.* 2003; 64: 128-39.
- [56] Yokomaku Y, Sugimoto T, Kume S, Araki S, Isshiki K, Chin-Kanasaki M, *et al.* Asialoerythropoietin prevents contrast-induced nephropathy. *J Am Soc Nephrol.* 2008; 19: 321-8.
- [57] Duan S, Zhou X, Liu F, Peng Y, Chen Y, Pei Y, *et al.* Comparative cytotoxicity of high-osmolar and low-osmolar contrast media on HKCs *in vitro*. *J Nephrol.* 2006; 19: 717-24.
- [58] Heinrich M, Scheer M, Heckmann M, Bautz W, Uder M. Reversibility and time-dependency of contrast medium induced inhibition of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) conversion in renal proximal tubular cells *in vitro*: comparison of a monomeric and a dimeric nonionic iodinated contrast medium. *Invest Radiol.* 2007; 42: 732-8.
- [59] Yang JS, Lu CC, Kuo SC, Hsu YM, Tsai SC, Chen SY, *et al.* Autophagy and its link to type II diabetes mellitus. *Biomedicine. (Taipei)* 2017; 7: 8.
- [60] Jensen H, Doughty RW, Grant D, Myhre O. The effects of the iodinated X-ray contrast media iodixanol, iohexol, iopromide, and ioversol on the rat kidney epithelial cell line NRK 52-E. *Ren Fail.* 2011; 33: 426-33.
- [61] Ko GJ, Bae SY, Hong YA, Pyo HJ, Kwon YJ. Radiocontrast-induced nephropathy is attenuated by autophagy through regulation of apoptosis and inflammation. *Hum Exp Toxicol.* 2016; 35: 724-36.
- [62] Kolyada AY, Liangos O, Madias NE, Jaber BL. Protective effect of erythropoietin against radiocontrast-induced renal tubular epithelial cell injury. *Am J Nephrol.* 2008; 28: 203-9.
- [63] He X, Yang J, Li L, Tan H, Wu Y, Ran P, *et al.* Atorvastatin protects against contrast-induced nephropathy *via* anti-apoptosis by the up-regulation of Hsp27 *in vivo* and *in vitro*. *Mol Med Rep.* 2017; 15: 1963-72.
- [64] Sayarlioglu H, Okuyucu A, Bedir A, Salis O, Yenen E, Bekfilavioglu G, *et al.* Is there any role of epithelial to mesenchymal transition in the pathogenesis of contrast nephropathy? *Ren Fail.* 2016; 38: 1249-55.